RDPAC: CRO Output Of China Will Double To RMB 11 Billion By 2015
This article was originally published in PharmAsia News
In its research report on innovation enhancement in China’s pharma industry released on Dec. 2, the R&D-based Pharmaceutical Association Committee (RDPAC) predicted that the country’s CRO (contract research organization) sector output will double to RMB 11 billion by 2015.
You may also be interested in...
Corindus Vascular Robotics Inc. expects its CorPath GRX robotic intervention system will eventually be part of a widespread system of "telerobotic" intervention sites operated by specialists located far away. See what Tejas Patel, an interventional cardiologist at the Apex Heart Institute in Ahmedabad, India, said about it here.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
The latest oncology development news and highlights from our US FDA Performance Tracker.